Hepatitis C Medications: Update on New Drugs

News and Alerts

• FDA Drug Safety Communication, March 1, 2012
  Interactions between certain HIV or hepatitis C drugs and cholesterol-lowering statin drugs can increase the risk of muscle injury.
• Important Drug Warning for HIV-HCV Coinfection, February 6, 2012
  The effectiveness of boceprevir and ritonavir-boosted HIV protease inhibitors may be significantly reduced when co-administered

Clinician Resources

• Guidance for Hepatitis C Treatment Monitoring
  Monitoring Patients on Pegylated Interferon + Ribavirin ± Protease Inhibitor (Boceprevir or Telaprevir), March 2012

• Boceprevir
  • Drug Monograph
• Telaprevir
  • Drug Monograph
• Update on the Management and Treatment of Hepatitis C Virus Infection
  Recommendations from the Hepatitis C Resource Center and the National Hepatitis C Program Office, May 2012

Patient Education

• Triple Therapy Workbooks (30-page booklets)
  July 2012
• New Therapies for Hepatitis C (brochure)
  March 2012
• Taking Your Hepatitis C Triple Therapy (1-page handout)
  February 2012
• Hepatitis C Medications: A Review and Update for Patients
  May 6, 2011

Journal Articles

• An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
  Ghany MC, Nelson, DR, Strader, DB, et al. Hepatology, Vol. 54, No. 4, 2011, 1433-1444.
• Managing Hepatitis C in the VA Health Care System.
  Durfee JM, Czarnogorski M, Backus LI, et al. Fed Practitioner Supplement. August 2011; 28(3) (digital edition with audio clips).
• Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection.
  Jacobson IM, McHutchison JG, Dusheiko G, et al. N Engl J Med. 2011 Jun 23;364(25):2405-16.
• Telaprevir for retreatment of HCV infection.
  Zeuzem S, Andreone P, Pol S, et al. N Engl J Med. 2011 Jun 23;364(25):2417-28.
• The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus Genotype 1 Infection, But With Issues Still Pending [Review Article]
  Pawlotsky JM. Gastroenterology. 2011 Mar;140(3):746-54.
• Boceprevir for untreated chronic HCV genotype 1 infection.
  Poordad F, McCone J Jr, Bacon BR, et al. N Engl J Med. 2011 Mar 31;364(13):1195-206.
• Boceprevir for previously treated chronic HCV genotype 1 infection.
  Bacon BR, Gordon SC, Lawitz E, et al. N Engl J Med. 2011 Mar 31;364(13):1207-17.
• Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.
  Marcellin P, Forns X, Goeser T, et al. Gastroenterology. 2011 Feb;140(2):459-468.
• Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.
  Kwo PY, Lawitz EJ, McCone J, et al. Lancet. 2010 Aug 28;376(9742):705-16.
• Telaprevir for previously treated chronic HCV infection.
  McHutchison JG, Manns MP, Muir AJ, et al. N Engl J Med. 2010 Apr 8;362(14):1292-303.